Equities research analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce sales of $14.80 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Antares Pharma’s earnings. The lowest sales estimate is $12.11 million and the highest is $17.30 million. Antares Pharma reported sales of $14.20 million in the same quarter last year, which would suggest a positive year over year growth rate of 4.2%. The company is expected to announce its next quarterly earnings report on Tuesday, March 13th.
On average, analysts expect that Antares Pharma will report full-year sales of $14.80 million for the current fiscal year, with estimates ranging from $52.58 million to $58.20 million. For the next fiscal year, analysts expect that the business will report sales of $77.33 million per share, with estimates ranging from $64.00 million to $101.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.01 million. The company’s quarterly revenue was up 11.9% compared to the same quarter last year.
Shares of Antares Pharma (NASDAQ ATRS) opened at $1.93 on Tuesday. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69.
Several hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. lifted its holdings in shares of Antares Pharma by 5.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 560,936 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 27,360 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Antares Pharma by 95.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 59,413 shares of the specialty pharmaceutical company’s stock worth $192,000 after acquiring an additional 28,940 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after acquiring an additional 30,000 shares during the last quarter. Capital Advantage Inc. bought a new position in shares of Antares Pharma in the third quarter worth about $110,000. Finally, Alliancebernstein L.P. bought a new position in shares of Antares Pharma in the second quarter worth about $119,000. 34.88% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Antares Pharma Inc (ATRS) Expected to Post Quarterly Sales of $14.80 Million” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/06/antares-pharma-inc-atrs-expected-to-post-quarterly-sales-of-14-80-million.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.